Bio Essence

Bio Essence Stock-Based Compensation

Stock-Based Compensation (SBC) of Bio Essence (BIOE) as of Oct 24, 2026.

Stock-Based Compensation

0.00USD

Last updated:

Stock-Based Compensation (SBC) of Bio Essence is 2021 0.00 USD. Stock-Based Compensation (SBC) of Bio Essence was 2020 8,890.00 USD. It decreases by % lower compared to the previous year.

The Bio Essence Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2019
78,610.00 USD
Jan 1, 2020
8,890.00 USD
Jan 1, 2021
0.00 USD
The Bio Essence Stock-Based Compensation history
YEARStock-Based CompensationYoY
0.00USD-100.00%
8,890.00USD-88.69%
78,610.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Essence Stock analysis

What does Bio Essence do? Bio Essence Corp. generates revenue through its three subsidiaries: Bio Essence Pharmaceutical (BEP), which operates as a health supplement original equipment manufacturer (OEM) service provider; Bio Essence Herbal Essentials (BEH), which targets healthcare practitioners with herbal products including granules, capsules, pills, and tablets, and offers special formulation services; and McBE Pharma (McBE), which develops, manufactures, and sells prescription drugs. The company's products are sold directly to healthcare practitioners such as dietitians and nutraceutical practitioners, who then recommend them to their patients. BEH specifically serves practitioners in the integrative healthcare market, providing both standard and custom-formulated herbal supplements. BEP functions as an OEM for health supplement manufacturers, producing private-label products under other brands. McBE Pharma focuses on prescription drugs, targeting healthcare providers for direct sales. The firm's direct connections with practitioners enable it to reach end consumers through professional recommendations rather than retail channels. Bio Essence Herbal Essentials Inc. (BEH) emphasizes its role in connecting practitioners with patients through tailored herbal supplement solutions. The company's revenue streams are derived from the sale of herbal health supplements, vitamin nutritional supplements, and prescription drugs. BEH's target segment includes practitioners who specialize in integrative healthcare, such as dietitians and nutraceutical practitioners, who use the company's products to support patient care. McBE Pharma's segment consists of healthcare providers seeking prescription drug solutions for their patients. BEP serves as a manufacturing partner for other supplement brands, supplying OEM services. Bio Essence is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Essence stock

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Bio Essence since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Bio Essence historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Bio Essence

All Key Metrics — Bio Essence